Eloralintide Research Guide: Amylin-Agonist Mechanism & Phase 2 Trial Data

Following the retatrutide guide, Lilly's pipeline doesn't stop at triple agonists. There's another compound moving through their obesity research program that works on a completely different pathway, and the early trial data is genuinely notable: eloralintide, an amylin receptor agonist that posted 20%+ weight-loss findings in a Phase 2 trial. This guide breaks down what it is, how it differs from everything else in this space, and where the research actually stands.

What Is Eloralintide?

Eloralintide (research code LY3841136) is a synthetic peptide developed by Eli Lilly. It belongs to a completely different drug class than retatrutide, tirzepatide, or semaglutide — instead of targeting GLP-1, GIP, or glucagon receptors, it's a selective amylin receptor agonist.

Amylin is a hormone the pancreas already makes alongside insulin. It is studied for its role in appetite regulation and satiety signaling — a different mechanism entirely from the GLP-1 family, which is exactly why the compound is generating research interest. It is not framed as a replacement for GLP-1 compounds; it is a different research target for the same overall problem, and Lilly is studying it both alone and in combination with tirzepatide.

• Chemical Classification: Amylin receptor agonist (AMY1R-selective)
• Development Status: Phase 3 clinical trials, enrollment underway as of 2026
• Developer: Eli Lilly and Company

The "Selective" Part Is the Whole Point

Amylin analogs aren't new — Novo Nordisk's cagrilintide (the amylin half of CagriSema) has been the one to beat in this class. What makes eloralintide different is receptor selectivity.

Amylin can activate a few related receptors, including one called the calcitonin receptor (CTR). Older, non-selective amylin compounds activate CTR along with the amylin receptors, and CTR activation is one of the mechanisms researchers link to nausea and food-aversion adverse events reported in trials. Eloralintide was specifically engineered to hit the amylin 1 receptor (AMY1R) far more selectively — Lilly's own preclinical data shows it activating AMY1R roughly 12 times more potently than CTR.

In animal studies, that selectivity showed up as a real difference: eloralintide caused significantly less "conditioned taste avoidance" (a lab proxy for nausea-driven food aversion) in rats compared to cagrilintide. The bet Lilly is making is that a more targeted molecule means comparable or comparable or better weight-loss findings with a milder adverse-event profile — and so far, the human trial data supports that hypothesis.

What Does the Research Actually Show?

Phase 1: Proof of Concept

Eloralintide's first human data came from two Phase 1 trials. A single-ascending-dose study in healthy participants tested doses from 0.04 to 12 mg and was generally well tolerated. A separate 12-week multiple-ascending-dose study in 100 participants with obesity or overweight (average BMI 32.6) found:

• Weight loss up to 11.3% at 12 weeks in the highest-response cohort
• As little as 2.6% in the lowest-dose cohort
• Adverse events reported in the trial were mostly mild — of the participants who reported adverse events, the large majority were mild in severity, with a small number of moderate GI events (including one case of vomiting)

That's a strong early signal for just a 12-week trial period.

Phase 2: The Data That Got Everyone's Attention

The real headline came from a 48-week Phase 2 trial of 263 adults with obesity or overweight (with at least one weight-related health complication, no type 2 diabetes), published in The Lancet and presented at ObesityWeek in November 2025.

Every treatment arm beat placebo by a wide margin, and the trial hit its primary endpoint across the board. Tolerability was described as favorable — mild-to-moderate GI symptoms were the most common issue, and incidence was similar to placebo in the lower-dose groups.

For comparison, Novo Nordisk's CagriSema (cagrilintide + semaglutide combined) has posted 20–23% weight loss at 68 weeks, and their newer amycretin candidate reported around 22% at 36 weeks. Eloralintide is putting up comparable numbers as a single agent, at 48 weeks, in a class Lilly entered later than its competitors — which is part of why analysts have taken notice.

What's Next: Phase 3

Based on those Phase 2 results, Lilly moved straight into Phase 3. Several large studies are already recruiting:

• ENLIGHTEN-1 — obesity/overweight without type 2 diabetes, started February 2026, estimated completion in 2028
• ENLIGHTEN-2 — obesity/overweight with type 2 diabetes, started December 2025, estimated completion in 2028
• ENLIGHTEN-3 — obesity/overweight with moderate-to-severe obstructive sleep apnea

Lilly also tested eloralintide combined with tirzepatide, a combo called EloraTZP. In a 48-week Phase 2b trial of adults with obesity or overweight and type 2 diabetes, the top dose combo showed 23.3% average weight loss vs 14.8% for tirzepatide alone. Side effect dropouts were higher with the combo, and Lilly plans to start Phase 3 trials of a single-injection version by the end of 2026. Full breakdown: EloraTZP Results Explained.

Where This Sits in the Bigger Picture

The amylin space has gotten crowded fast. Novo Nordisk, AbbVie, Roche, and Zealand Pharma all have amylin-targeting candidates in some stage of development, and industry analysts increasingly view amylin agonists — alone or paired with a GLP-1/GIP drug — as the next real leap in this category, rather than another marginal iteration.

Eloralintide's pitch is specificity: comparable efficacy to the non-selective options, with a tolerability edge from hitting a narrower target. Whether that edge holds up at scale, and whether the combination studies with tirzepatide show a meaningful boost over either compound alone, are the two questions worth watching as Phase 3 data starts to roll in.

Honest Gaps: What We Don't Know Yet

• No long-term data. 48 weeks is the longest published dataset so far. Durability, weight regain after stopping, and rare long-term effects are all unknowns.
• Limited population diversity so far. Trial populations to date have been relatively narrow; broader Phase 3 enrollment (already underway) should fill this in.
• Combination data is early. The first EloraTZP (eloralintide + tirzepatide) Phase 2b results came out in September 2026 and looked strong, but more people quit due to side effects, and the data only covers people with type 2 diabetes. See the EloraTZP breakdown.
• Regulatory path and timeline are genuinely unclear. This compound just started Phase 3. Any future filing or approval decision is realistically years out and depends entirely on how those trials read out.

Frequently Asked Questions

What is eloralintide?

Eloralintide (LY3841136) is an investigational amylin receptor agonist developed by Eli Lilly. It's a selective amylin receptor agonist being studied for weight loss in adults with obesity or overweight, with and without type 2 diabetes.

How is eloralintide different from retatrutide or tirzepatide?

Retatrutide and tirzepatide are GLP-1-family drugs that target GLP-1, GIP, and/or glucagon receptors. Eloralintide works on an entirely different pathway — the amylin receptor — and is engineered to be more selective for that receptor than older amylin compounds, which trial data suggests may be associated with fewer nausea-related adverse events.

How much weight loss has eloralintide shown in trials?

In a 48-week Phase 2 trial, weight loss ranged from 9.5% to 20.1% across dose groups, compared to 0.4% with placebo. All doses met the trial's primary endpoint.

Is eloralintide the same as cagrilintide?

No, but they're in the same drug class (amylin receptor agonists). Cagrilintide is Novo Nordisk's compound, and it's non-selective — it also activates the calcitonin receptor. Eloralintide is engineered to be more selective for the amylin receptor specifically, which early animal and human data suggests may improve tolerability.

Is eloralintide approved for use?

No. Eloralintide is not approved for human or veterinary use and is currently in Phase 3 trials. Any future regulatory filing or approval will depend entirely on the outcome of those trials, which are expected to run into 2028.

Can eloralintide be combined with tirzepatide?

Lilly has tested this combination, called EloraTZP, in a 48-week Phase 2b trial. The top dose combo showed 23.3% average weight loss compared to 14.8% for tirzepatide 15 mg alone, in adults with obesity or overweight and type 2 diabetes. More participants stopped because of side effects in the combo groups. Lilly plans to start Phase 3 trials by the end of 2026. This is clinical trial data only and is not an instruction for combining research compounds.

Disclaimer: All content on ResearchPepHub is for educational and research purposes only. These compounds are supplied strictly for laboratory research and are not approved for human or veterinary use. Nothing on this site is medical advice or an instruction for use in humans. This post covers published clinical trial data for educational purposes. Research Pep Hub has no affiliate relationship connected to this compound and earns nothing from this page.

Tags: eloralintide, LY3841136, amylin, Eli Lilly, obesity trial research, obesity research, cagrilintide comparison, EloraTZP